Rubitecan

DB06159InvestigationalSmall molecule

Investigated for use/treatment in pancreatic cancer, leukemia (unspecified), melanoma, ovarian cancer, and cancer/tumors (unspecified).

Mechanism: Rubitecan prevents DNA from unwinding during replication via DNA topoisomerase 1, therefore interfering with tumor growth.
Curator reviewed
Primary indication: Investigated for use/treatment in pancreatic cancer, leukemia (unspecified), melanoma, ovarian cancer, and cancer/tumors (unspecified).Curator reviewed
Formula / weight: C₂₀H₁₅N₃O₆ · 393.355 g/mol (avg)
Also known as: 1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 4-ETHYL-4-HYDROXY-10-NITRO-, (4S)- · 9-NC · 9-nitrocamptothecin
Code names: RF-2000 · RFS-2000

Resolves to

Compound

Structure

InChIKeyVHXNKPBCCMUMSW-FQEVSTJZSA-NSMILESCC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC=C(C1=C3)[N+]([O-])=O)C2=O

Targets

What you can answer from here — as of August 26, 2024

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

19Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rubitecan, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.